Mechanisms and Management

  • Paul L. Wood

Part of the Contemporary Neuroscience book series (CNEURO)

Table of contents

  1. Front Matter
    Pages i-x
  2. Microglia

    1. Front Matter
      Pages xi-xi
    2. Hiroyuki Kato
      Pages 91-107
    3. Dana Giulian, Jun Li
      Pages 109-125
  3. Acute Phase Proteins

    1. Front Matter
      Pages 127-127
    2. Katharyn Spiegel, Mark R. Emmerling, Scott R. Barnum
      Pages 129-176
    3. Joseph Rogers, W. S. T. Griffin
      Pages 177-193
  4. Cytokines

    1. Front Matter
      Pages 195-195
    2. David Martin, Gerald Miller, Tim Neuberger, Jane Relton, Norman Fischer
      Pages 197-219
    3. Linda Ott, Craig McClain, Stephen Scheff, Jimmi Hatton, Byron Young
      Pages 221-249
  5. Free Radicals

    1. Front Matter
      Pages 263-263
    2. Kenneth Hensley, Quentin N. Pye, Tahereh Tabatabaie, Charles A. Stewart, Robert A. Floyd
      Pages 265-281
  6. Miscellaneous Mediators

    1. Front Matter
      Pages 297-297
    2. Ian W. Rodger, Chi-Chung Chan
      Pages 355-371
  7. Back Matter
    Pages 373-375

About this book


In an unprecedented integration of cutting-edge ideas in immunology with clinical neuropathological findings, Neuroinflammation: Mechanisms and Management reviews and synthesizes our knowledge of the inflammatory mediators and cells involved in neurodegenerative diseases. Beginning with a detailed review of the role of biochemical mediators in neuronal loss and the mechanisms of cell death, the distinguished contributors critically examine research on the design of specific pharmacological agents to inhibit defined points in the neuroinflammatory cascade. They also address the molecular, cellular, and therapeutic actions of first generation agents, as well as their potential clinical relevance to AIDS dementia, Alzheimer's disease, amyotropic lateral sclerosis (ALS), Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease, and stroke.

Neuroinflammation: Mechanisms and Management offers a remarkable new synthesis that will play a key role in developing the molecular targets now emerging in neuropharmacological drug design, and so lead to a new generation of drugs for neurologists to use in the treatment of a wide variety of both acute and chronic neurodegenerative disorders.


Alzheimer Nervous System Parkinson alzheimer's disease cognition dementia head injury neurodegenerative disorders spinal cord

Editors and affiliations

  • Paul L. Wood
    • 1
  1. 1.Pharmacology, CoCensys, Inc.IrvineUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods